Alpha Cognition (NASDAQ:ACOG) Posts Quarterly Earnings Results, Misses Expectations By $0.01 EPS

Alpha Cognition (NASDAQ:ACOG) released its earnings results on Thursday. The company reported ($0.40) earnings per share for the quarter, missing the consensus estimate of ($0.39) by ($0.01), Zacks reports. Alpha Cognition had a negative net margin of 232.23% and a negative return on equity of 58.35%.

Here are the key takeaways from Alpha Cognition’s conference call:

• ZUNVEYL net product revenue rose 71% sequentially to approximately $6 million in Q2 2026, with demand increasing each month and June marking the strongest month to date.
• Commercial adoption continued to deepen, with 1,347 active prescribers, 1,095 nursing homes placing prescriptions, and repeat utilization from approximately 76% of writers and 81% of prescribing homes.
• Management highlighted positive BEACON findings across cognition, neuropsychiatric symptoms, activities of daily living, and polypharmacy, while CONVERGE data is expected in Q3 2026 and RESOLVE remains on track to complete in Q2 2027.
• Payer and formulary expansion remains the largest near-term constraint; broad activation has been slower than expected, with coverage holding at roughly 74% and no significant formulary wins reported in Q2.
• The company reduced 2026 operating-expense guidance to $50 million-$54 million from $54 million-$58 million, ended Q2 with $41.4 million in cash, and reiterated its target of reaching operating profitability in 2027.

Alpha Cognition Price Performance

Shares of Alpha Cognition stock traded down $0.32 during trading on Thursday, hitting $8.63. 200,919 shares of the company’s stock traded hands, compared to its average volume of 64,023. The company has a market cap of $187.88 million, a PE ratio of -6.39 and a beta of 2.31. The firm’s fifty day moving average price is $7.63 and its 200 day moving average price is $6.49. Alpha Cognition has a twelve month low of $4.50 and a twelve month high of $10.00.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in ACOG. Geode Capital Management LLC acquired a new stake in Alpha Cognition during the second quarter valued at approximately $112,000. Massar Capital Management LP bought a new stake in shares of Alpha Cognition in the 2nd quarter valued at approximately $116,000. Two Sigma Investments LP acquired a new position in shares of Alpha Cognition in the 3rd quarter worth approximately $148,000. Connective Capital Management LLC acquired a new position in shares of Alpha Cognition in the 3rd quarter worth approximately $312,000. Finally, Marshall Wace LLP bought a new position in shares of Alpha Cognition during the 2nd quarter worth approximately $600,000.

Analyst Upgrades and Downgrades

Several equities analysts have commented on ACOG shares. Craig Hallum initiated coverage on Alpha Cognition in a report on Friday, April 17th. They issued a “buy” rating and a $14.00 price target for the company. Raymond James Financial assumed coverage on Alpha Cognition in a report on Friday, July 10th. They set an “outperform” rating and a $20.00 price objective on the stock. HC Wainwright restated a “buy” rating and set a $18.00 price objective on shares of Alpha Cognition in a research report on Friday, May 22nd. Maxim Group began coverage on Alpha Cognition in a research note on Friday, May 29th. They issued a “buy” rating and a $12.00 target price for the company. Finally, Wall Street Zen cut Alpha Cognition from a “hold” rating to a “sell” rating in a research report on Saturday, May 2nd. Four equities research analysts have rated the stock with a Buy rating, According to data from MarketBeat, the company has an average rating of “Buy” and a consensus price target of $16.00.

About Alpha Cognition

Alpha Cognition, Inc is a clinical stage biopharmaceutical company that develops treatments for underserved neurodegenerative diseases such as Alzheimer’s Dementia and Amyotrophic Lateral Sclerosis. The company was founded in 2000 and is headquartered in Vancouver, Canada.